Clinical efficacy of external beam radiotherapy complementing incomplete transarterial chemoembolization for hepatocellular carcinoma
- Authors
- Park, Sunmin; Yoon, Won Sup; Jang, Mi Hee; Rim, Chai Hong
- Issue Date
- 1-Dec-2020
- Publisher
- TAYLOR & FRANCIS LTD
- Keywords
- Hepatocellular carcinoma; liver neoplasm; transarterial chemoembolization; external beam radiotherapy; stereotactic body radiation therapy
- Citation
- INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, v.96, no.12, pp.1541 - 1549
- Indexed
- SCIE
SCOPUS
- Journal Title
- INTERNATIONAL JOURNAL OF RADIATION BIOLOGY
- Volume
- 96
- Number
- 12
- Start Page
- 1541
- End Page
- 1549
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/50857
- DOI
- 10.1080/09553002.2020.1830316
- ISSN
- 0955-3002
- Abstract
- Purpose External beam radiotherapy (EBRT) has been commonly applied as salvage or a combination locoregional modality after transarterial chemoembolization (TACE) for hepatocellular carcinomas (HCCs). This study reports oncologic outcomes and feasibility after application of the two modalities in our center. Methods Forty consecutive patients who underwent EBRT due to incomplete responses of TACE were evaluated. Fourteen patients (35.0%) received stereotactic body radiotherapy (SBRT) and the remaining patients received conventionally fractionated radiotherapy (RT). A majority of patients who underwent SBRT received doses of 27 to 48 Gy in 3-4 fractions [median EQD(2)(Equivalent dose in 2 Gy per fraction radiotherapy): 57.0 Gy]. Conventionally fractionated RT was performed with a median EQD(2)of 47.8 Gy. Results The median follow-up duration was 14.4 months (range: 2.6-83.0 months). A majority (77.5%) of patients were regarded as having Child-Pugh grade A. The median tumor size was 3.4 cm (range: 0.8-20.1 cm). Ten patients (25.0%) had thrombosis at a main portal branch. The 1- and 2-year overall survival (OS) and progression-free survival (PFS) rates were 82.2% and 42.1% and 55.8% and 32.1%, respectively. The local control rates were 89.1% and 89.1% at 1 and 2 years, respectively. The albumin level was a significant factor affecting OS (p = .002), and the BCLC stage significantly affected PFS (p = .001). Intrahepatic, out-of-field recurrence was the main cause of disease progression (60.0%), and distant metastasis developed in 12 patients (30.0%) during follow-up. Non-classic radiation-induced liver disease was seen in five (12.5%) patients, and two (5%) patients experienced grade >= 3 hepatic toxicities. Conclusions EBRT after incomplete TACE was feasible and yielded favorable oncologic outcomes. However, disease progression related to intrahepatic failure remained a hindrance.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.